Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05463367CT.gov Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opiate Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naproxen (this asset) | Northwestern University | P2 | CCC · 53 |
| Buprenorphine | Erin Winstanley | P4 | BBB |
| 17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE | University of California, San Francisco | P4 | BB |
| Lidocaine | University Medical Centre Ljubljana | P4 | BB |
| Marcaine | Denver Health and Hospital Authority | P4 | BB |
| Gabapentin | Brigham and Women's Hospital | P4 | BB |
| Epclusa | Saskatchewan Health Authority - Regina Area | P4 | BB |
| Sufentanyl | West Virginia University | P4 | BB |
| Genvoya | Saskatchewan Health Authority - Regina Area | P4 | BB |
+20 more in the Opiate Dependence cohort
Other indications for Naproxen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | A · 80 |
| Headache Disorder | — | P4 | BBB · 72 |
| Osteoarthritis, Knee | — | P3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naproxen in Opiate Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naproxen-opiate-dependence
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →